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Food:  An Unrecognized Source of 
Loop Diuretic Resistance
Robert L. Bard, M.A., Barry E. Bleske, Pharm.D., and John M. Nicklas, M.D.
Food significantly affects the pharmacokinetics of oral loop diuretics in
healthy individuals, but studies have not been performed in patients with
edema.  Because of this omission, food’s effect on pharmacokinetics has been
overlooked and may decrease the pharmacodynamic response in patients who
rely on diuretics.  Despite this potential interaction, reference manuals do not
provide warnings about the effects of food on loop diuretic absorption.  We
reviewed the published human studies investigating the effects of food on
loop diuretics.  Peak plasma concentrations and urinary recovery were
significantly decreased when taken with food, but only one study showed a
corresponding decrease in total urine output, which is likely related to the
diuretic threshold effect.  These healthy subjects probably were always above
the diuretic threshold under both fed and fasting conditions and thus could
not augment their urine output.  Based on these data in healthy subjects, the
special implications for patients who routinely take diuretics are discussed.
Therefore, food is more likely to have a clinical effect on the diuretic
threshold given its effect in healthy subjects and the special considerations for
patients with edema.  Additional studies are needed to help answer these
questions.  Until such data are available, the most conservative, effective
clinical approach is to administer oral loop diuretics without food.
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Conclusion
Loop diuretics are a common class of drug
used in the treatment of chronic conditions such
as chronic heart failure (CHF) and renal failure.
Food has long been known to significantly affect
the pharmacokinetics of loop diuretics.
However, the clinical significance of these data is
not appreciated nor well known.
Mechanism of Action of Loop Diuretics
The loop diuretics—furosemide, bumetanide,
torsemide, and ethacrynic acid—act primarily
and directly at the luminal surface of the
ascending limb of the loop of Henle to prevent
sodium chloride reabsorption from the tubule by
inhibiting an ion transport protein sodium-
potassium-chloride symporter.  These drugs are
highly protein bound in the blood and do not
enter the tubular lumen through glomerular
filtration; they are secreted from the blood into
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the urine through the organic acid transport
pathway in the straight segment of the proximal
tubule.1 The transport pathway avidly secretes
all loop diuretics and is relatively independent of
the flow to the tubule.  Only other organic acids,
such as probenecid, alter loop diuretic secretion
by competing for transport in the proximal
tubule.
The inability to reabsorb salt in the loop region
of the nephron results in a loss of the high
medullary osmolality, thus decreasing the ability
of the kidney to reabsorb water and helping to
produce hypotonic urine.2 Loop diuretics reach
the tubular lumen primarily as unmetabolized
drug, and renal secretion accounts for the
elimination of most of an administered dose,
except in patients with advanced renal failure.
The proximal tubule rapidly secretes loop
diuretics, clearing the blood within hours and
producing relatively short-lived periods of
diuresis.
Loop diuretics also act indirectly to increase
urine output by stimulating renal prostaglandin
synthesis and vasodilating the prerenal arterioles.
As a consequence, renal blood flow is increased,
and the filtered sodium load at the tubule is
increased; this allows the loop diuretic to prevent
reabsorption of more sodium from the tubule.
Diuretic effects can be limited by renal
hypoperfusion and prostaglandin synthesis
inhibitors, such as nonsteroidal antiinflammatory
drugs.  Such drugs can prevent one third of the
increased renal blood flow attributed to loop
diuretics.
In addition to the direct and indirect effects,
the response to loop diuretics is determined by
the rate of delivery of drug into the urine.  To
achieve an effective diuresis, a threshold
concentration of diuretic must reach the site of
action.  The amount of drug must be sufficient to
reach the steep portion of a sigmoid-shaped dose-
response curve (Figure 1).  Once achieved, this is
commonly referred to as reaching the diuretic
threshold.  Therefore, the pharmacodynamic
response to diuretics is correlated with urinary
diuretic excretion.1, 3
Since urinary diuretic excretion correlates with
diuresis, the amount of drug absorbed may
directly affect the pharmacodynamic response.1, 3
Although these drugs reach the tubular lumen by
active secretion, drug concentrations in the blood
drive the transport pathway in the proximal
tubule.  Based on this, diuretic efficiency as
evaluated by urine drug concentration is
dependent on drug absorption into the blood.
Thus, any alteration in drug absorption may alter
the pharmacodynamic response.
Food is known to alter the absorption of a
number of drugs and significantly affect the
pharmacodynamic response.  However, the effect
of food on the absorption of oral loop diuretics
has been overlooked, and it may affect the
pharmacodynamic response.  Despite this
potential interaction, reference manuals, such as
the Physicians’ Desk Reference,4 do not provide
warnings about the effects of food on loop
diuretic absorption.  In addition, neither
physicians nor pharmacists commonly counsel
patients about the timing of loop diuretic
ingestion and meals, and some material5 instructs
patients to take loop diuretics with meals.  This is
probably because a well-designed study has not
been conducted involving patients who take
diuretics for edema.
In some patients, food may prevent effective
diuresis because the patients may be just above
the diuretic threshold when they take their loop
diuretics while fasting, but they may not reach
diuretic threshold when they take their diuretics
with food.
Effects of Food on Loop Diuretics
To examine the effects of food on the pharmaco-
kinetics and pharmacodynamics of the oral loop
diuretics, furosemide, bumetanide, and torsemide,
we aggregated data from human studies.  A
literature review revealed eight published articles
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Figure 1. To achieve an effective diuresis, the amount of
drug must be sufficient to reach the steep portion of a
sigmoid-shaped dose-response curve like the one shown in
this figure.  Once achieved, this is commonly referred to as
reaching the diuretic threshold.
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over a span of 22 years that investigated the
effects of food on loop diuretics (Table 1).1, 3, 6–11
Furosemide
Six of the eight published articles regarding
food intake and loop diuretics evaluated
furosemide.  In 1974, the first study was
published in which the primary focus was a
comparison of aqueous and tablet forms of
furosemide; the effect of food was a secondary
aim.7 This study involved eight healthy
volunteers under fasting and fed conditions.
However, not all participants completed all arms
of the study; only two subjects ingested the
solution with a meal and the other three arms
had six or fewer subjects.
Subjects took oral furosemide 80 mg after
breakfast; urine losses were replaced with
Ringer’s lactate solution.  Blood was obtained for
pharmacokinetic studies for a total of 4 hours 40
minutes.  Urine was collected, but urinary
recovery was not reported because of errors in
the assay system.
Food significantly impaired furosemide
absorption, as demonstrated by the maximum
concentration of drug (Cmax) and the time to
Cmax (Tmax).  In fact, Cmax was more than double
in the fasting versus the fed group in subjects
who took furosemide in tablet form.  Despite
632
Table 1.  A Review of the Methodology and Results of Studies Investigating the Effects of Food on Loop Diuretics
Methodology
Food vs Fasting,
Drug, Study Participants, Dose Formulation
Year of Study Health Status (mg) Volume Replacement (no. of patents)
Furosemide
19747 8, healthy 80 i.v. Ringers by volume Fasting, tablet (5)
Meal, tablet (6)
Fasting, solution (6)
Meal, solution (2)
19853 8, healthy 40 Water 200 ml/hr Fasting, tablet
Meal, tablet
Meal, solution
19859 10, respiratory 40 NA 30 min preprandial, tablet
failure
30 min postprandial, tablet
198610 10, healthy 40 Water, 150 ml/hr Fasting, tablet (10)
Meal, tablet (10)
Heavy meal, tablet (5)
19951 28, healthy 60 Replaced volumes Fasting, Furix Retard
Meal, Furix Retard
Fasting, Lasix Retard
Meal, Lasix Retard
19968 8, healthy 40 Water 500 ml at hour 1, then Fasting, solution
i.v. sodium chloride by volume Meal, solution
Bumetanide
19766 6, healthy 1 Constant between treatments 30 min preprandial
3, CHF 30 min postprandial
19968 9, healthy 2 Water 500 ml at hour 1, then Fasting, solution
i.v. sodium chloride by volume Meal, solution
Torsemide
199511 14, healthy 10 Water ad libitum Fasting, tablet
30 min postprandial, tablet
AUC = area under the concentration-time curve; Tmax = time to peak serum concentration of drug; Cmax = peak serum concentration of drug;
NA = not available; ND = not done; Furix Retard, Lasix Retard = controlled-release formulations of furosemide.
aSignificantly different from fasting or preprandial (p<0.05).
bValues estimated from figures.
cSignificantly different from Lasix retard (p<0.05).
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significant pharmacokinetic differences, diuresis
was similar in the two groups.  This disparity
between pharmacokinetics and pharmacodynamics
probably occurred because the healthy participants
were all above diuretic threshold under both fed
and fasting conditions; thus, greater concentrations
of drug could not produce significant changes in
urine output.
More than a decade later, a 1985 study
evaluated the effect of food with furosemide in
eight healthy volunteers.3 As in the study
discussed above,7 the primary purpose was to
compare different forms of furosemide.  Subjects
took the drug in tablet and aqueous forms with
food, and in tablet and intravenous forms while
fasting.  Methodologic differences were noted
between fasting and fed conditions.  Under
fasting conditions oral furosemide 40 mg was
taken with 200 ml of water, but under fed
conditions it was taken with 200 ml of orange
juice after a meal that included tea.  In contrast,
other food and diuretic studies excluded
xanthine-containing foods.
Urine was collected at regular intervals over 8
hours; pharmacokinetic studies of the blood were
not performed.  Significantly less furosemide was
present in the urine during fed conditions
(p<0.01).  Despite greater concentrations of drug
while fasting, the average diuresis was greater in
fed subjects, although the difference was not
statistically significant.  It is unknown why there
was not a better correlation between urinary
excretion of furosemide and diuresis.  A potential
confounding factor in this study was the
coadministration of different liquids with
furosemide between the fed and fasting phases.
Tea may have affected diuresis under the fed
condition.  Despite these differences, the amount
633
Table 1.  (continued)
Results
Pharmacokinetics Pharmacodynamics
Urinary Recovery Absorption in Blood Diuresis Time Interval
Time (hrs) (mg) % of Dose AUC (mg•hr/L) Tmax (hrs) Cmax (mg/L) (ml) (hrs)
4 NA NA 3.93 1.0 2.3 ± 0.5 5144 ± 1752 12
4 NA NA ND 2.0a 1.0a 4836 ± 1304 12
4 NA NA 4.15 NA NA 4037 ± 1179 12
4 NA NA ND NA NA 5180 ± 764 12
8 14.0 ± 1.1 35 ± 3 ND ND ND 1950 ± 88 8
8 9.5 ± 0.4a 24 ± 1a ND ND ND 2130 ± 185 8
8 9.2 ± 0.8a 23 ± 2a ND ND ND 2250 ± 110 8
6 8.03 20 3.99 0.5b 3.99 867 6
24 11.55 29 ND ND ND 1689 24
6 6.35 16 2.71a 3.0b 2.71a 980 6
24 9.41 24 ND ND ND 1753 24
48 11.4 ± 2.5 29 ± 6 2.174 ± 0.668 1.4 0.933 ± 0.272 2072 ± 347 10
2668 ± 691 24
48 8.4 ± 1.4a 21 ± 4a 1.219 ± 0.153a 1.4 0.423 ± 0.153a 1640 ± 347 10a
2270 ± 397 24a
48 8.8 ± 1.8a 22 ± 5a 1.169 ± 0.313a 2.2a 0.356 ± 0.062a NA NA
24 11.38 ± 3.12c 19 ± 5 ND ND ND 4096 ± 1281 24
24 7.73 ± 1.67a, c 13 ± 3 ND ND ND 3817 ± 1283 24c
24 8.04 ± 3.32 13 ± 6 ND ND ND 3436 ± 1259 24
24 9.45 ± 1.83a 16 ± 3 ND ND ND 4347 ± 1374 24a
24 18.16 ± 3.16 45 ± 8 3.54 ± 0.82 0.69 ± 0.21 2.35 ± 0.49 ND ND
24 11.84 ± 2.44a 30 ± 6a 1.95 ± 0.72a 1.91 ± 0.93a 0.51 ± 0.19a ND ND
NA NA NA NA NA NA NA NA
NA NA NA NA NA NA NA NA
24 1.19 ± 0.168 60 ± 8 0.143 ± 0.023 0.53 ± 0.08 0.097 ± 0.015 ND ND
24 1.00 ± 0.312a 50 ± 16a 0.126 ± 0.025 1.36 ± 0.72a 0.036 ± 0.012a ND ND
24 2.37 ± 0.62 24 ± 6 3.357 ± 0.859 0.89 ± 0.37 1.466 ± 0.202 5000 ± 1100 24
24 2.35 ± 0.43 24 ± 4 3.424 ± 0.841 1.50 ± 0.64a 0.988 ± 0.269a 4700 ± 1400 24
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of drug excreted by the kidney was lower in the
group who took furosemide with food.
Another 1985 study is the only one that
involved subjects other than healthy volunteers.9
A subset of 10 patients with respiratory failure
received oral furosemide 40 mg 30 minutes
before or after breakfast.  This small study
evaluated the short-term diuretic effect.  Serum
concentrations of furosemide were measured at
0.5, 1.5, 3.0, and 6.0 hours after diuretic
ingestion.  The authors concluded that
furosemide taken before a meal improved
absorption, as demonstrated by a significantly
greater area under the concentration-time curve
(AUC), Tmax, and Cmax (p<0.01 for all three).
Diuresis was similar between the two groups;
however, fluid replacement during the study was
not addressed.
A year later, a study involving 10 healthy
volunteers reported a reduced effect of oral
furosemide 40 mg when given with food.10
Subjects ingested furosemide on separate days at
least 1 week apart, with or without a meal.  The
effects of a heavy breakfast were studied in a
subset of five of the subjects.  Blood was sampled
over 10 hours, and urine was collected for up to
48 hours.  Food significantly decreased both Cmax
and urine production (p<0.05).  Subjects taking
furosemide with food had significantly smaller
urinary recovery of the drug, which was
consistent with the significantly decreased
plasma AUC and Cmax values.
A 21% greater diuresis occurred at 10 hours
under the fasting versus fed condition.  The
pharmacokinetic and pharmacodynamic effects
of the heavy meal were nearly identical to those
of the standard meal, except that the heavy meal
increased the average Tmax from 1.4 to 2.2 hours.
Based on these data, the authors concluded that
furosemide should not be given with food.
Another decade passed before a 1995 study
was published that involved furosemide 60 mg
administered with food in 28 healthy subjects.1
As in other studies, determining the effect of food
was not the only aim.  This study compared the
effect of food on two different controlled-release
formulations of furosemide (Furix Retard and
Lasix Retard, neither of which has been approved
by the Food and Drug Administration).  Subjects
took furosemide while fasting or immediately
after consuming a high-fat breakfast.  Urine
samples were obtained over 24 hours; blood
samples were not obtained.
Differences were observed between the two
furosemide formulations.  When taken under
fasting conditions, urinary furosemide was
greater with Furix Retard than Lasix Retard.
Twenty-four hour urine volume was significantly
greater when subjects took Lasix Retard with
food, but no significant difference was noted with
Furix Retard.  The reason for this discrepancy is
unclear; the authors speculated that there may be
some type of difference in the capsule-coating
material of the two products.
The most recent study involving food and
furosemide, published in 1996, evaluated
furosemide 40 mg and bumetanide 2 mg in two
different crossover trials of healthy volunteers.8
Subjects underwent four different studies in a
randomized, crossover design that incorporated
the two factors:  fasting or fed conditions and
oral or intravenous forms of the drug taken.
Subjects took the drug while fasting or
immediately after eating breakfast.  The oral
furosemide was given as an aqueous solution in
100 ml of orange squash and then was washed
down with 100 ml of water.
Blood and urine were collected at regular
intervals over the first 8 hours; urine collection
was continued until 24 hours after dose
administration.  Only urinary drug content was
reported since the study was not controlled to
consider pharmacodynamic effects.  Taking the
drug with food was associated with a 30%
decrease in bioavailability.  Also, it significantly
decreased urinary recovery of furosemide
(p<0.001), Cmax (p<0.001), and AUC (p<0.01),
and significantly increased Tmax (p<0.01).  One
methodologic difference between this and the
other studies is that the subjects remained supine
for the entire study (except when urinating).
This is an important variable to consider because
body position affects renal blood flow and thus
can affect diuresis.
Bumetanide
Two studies have evaluated the effect of food
on bumetanide pharmacokinetics.6, 8 The first
was presented in extended abstract form and
provided scant data.6 The study was designed to
minimize the need to urinate after retiring to bed,
so bumetanide was taken either 30 minutes
before or immediately after dinner.  Urine
volumes were obtained hourly for 6 hours; blood
samples were not obtained.  No difference was
noted in total urine volumes, but there was a
significant difference in the pattern of diuresis.
Urine output the first hour was greater under
preprandial conditions, and diuresis was largely
634
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completed within 3 hours in those who took
bumetanide before versus after dinner.  The
authors concluded that patients are less likely to
interrupt their sleep to urinate when loop
diuretics are taken before rather than after
dinner.
The second study, described earlier, involved
bumetanide in a crossover with furosemide.8
Nine healthy men were given bumetanide 2 mg
as a solution, with or without food.  As with
furosemide, bumetanide significantly decreased
Cmax (p<0.001) and increased Tmax (p<0.05) but
had less effect on other pharmacokinetic
parameters (Table 1).  Bioavailability, AUC, and
urinary recovery were decreased when bumetanide
was taken with food, but the differences did not
reach statistical significance.  Therefore, the
authors concluded that food is a factor that may
influence the potency or pattern of diuresis, but
the effect may be less with bumetanide.
Torsemide
In the only study evaluating the effect of food
on torsemide pharmacokinetics, 14 healthy
volunteers participated in a 24-hour, open-label
study of oral torsemide 10 mg taken in fasting
condition or 30 minutes after a meal.11 Patients
were permitted to drink water ad libitum, and
urine was collected over the 24-hour study
period.  The food condition involved a high-fat,
high-carbohydrate meal.  Plasma samples
obtained at intervals up to 24 hours for
pharmacokinetics indicated that Cmax decreased
(p<0.001) and Tmax increased (p=0.013) when
torsemide was taken with food.  However, no
significant difference was noted in AUC
(p=0.452) or urinary excretion (p=0.820) over
the 24-hour study period.  The maximum urinary
excretion rate of torsemide was significantly
lower in the fed group, but this difference was
not reflected in urine output at 24 hours (5.0 ±
1.1 L fasting vs 4.7 ± 1.4 L fed).  These data
suggest that food decreases the rates of
absorption and urinary excretion of torsemide.
Discussion
This review yielded evidence demonstrating
that food affects the pharmacokinetics of loop
diuretics.  The glaring omission in the review is a
quality study involving patients with CHF.  The
absence of such a study in the published
literature indicates that the effect of food on loop
diuretics in patients with edema has been
ignored.  Among the available studies, the
differences in both methodology and results are
profound.
Study Comparison
The studies reviewed used different doses and
forms of diuretics, meals, sampling intervals, and
fluid replacement strategies.  These limitations
were further compounded by small sample sizes
and studies in which the effect of food was not
the primary outcome.  One study appeared to
provide the best information because it answered
the most concerns.10 The effect of food was the
primary outcome, and the study used the most
common diuretic (furosemide) in its most
common oral form.  Many of the other
furosemide studies involved questionable
methodologies with very small samples, different
primary aims, unavailable or uncommon forms of
the drug, or missing pharmacokinetic or
pharmacodynamic data.  In addition, scant data
are available regarding bumetanide and
torsemide.
Most studies demonstrated a significant
decrease in the rate and extent of loop diuretic
absorption along with a decrease in urinary
excretion (Table 1).  The effects were greatest in
studies comparing participants in both the fasting
and fed states, but pharmacokinetic differences
also were reported when comparing loop diuretic
ingestion before versus after a meal.
Correlation Between Pharmacokinetics and
Pharmacodynamics
The pharmacokinetic variable of interest
regarding loop diuretics is the amount of drug
recovered in the urine since the drug passes
through its active site of action.  One reason for
ignoring the food issue may be that clinicians
focus on urine output and not urinary drug
concentration.  With loop diuretics, urinary drug
content does not always correlate with urinary
volumes because of the threshold effect.
Every study found that food significantly
decreased the absorption of loop diuretic into the
blood, but only one10 reported a corresponding
decrease in urinary output.  This discrepancy
may be explained by situations in which the
doses were above diuretic threshold.  Regardless
of the amount of drug recovered in the urine,
more urine could not be produced because the
threshold was surpassed under both the fed and
fasting conditions.  A dose-ranging trial involving
these subjects could help determine the effect of
food on urine volume by giving a dose when the
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blunted diuretic absorption with food is below
threshold, but the fasting absorption remains
above threshold.
Another concern is the urine collection time
points.  The period of clinical importance is
approximately the first 6 hours.  During this
period, loop diuretics have their maximal effect,
and clinical decisions are likely to be made.  In
the above study,10 urine output was separated
over 1-hour periods, and the greatest difference
occurred over the first 5 hours.  In addition, both
this study and another study1 reported that
subjects who took furosemide with food never
made up for the lost diuresis after 24 hours.
Projections of Results from Healthy Subjects to
Patients
Healthy subjects have superior absorption
ability compared with patients with CHF or renal
disease.  Loop diuretics are a primary therapy for
patients with CHF, whose ability to absorb
diuretics is impaired compared with healthy
subjects, especially when decompensated.  As
displayed in Figure 2, patients with CHF have
lower Cmax and longer Tmax than healthy
subjects,12–17 which translates into a decreased
ability to transport drug into the urine compared
with healthy subjects.14, 15, 18 These effects are
likely to be multifactorial and may be explained
by delayed gastric emptying, decreased gastro-
intestinal motility, decreased renal function, and
bowel wall edema associated with CHF.11, 13, 14, 19–23
Theoretically, patients who take their diuretic
with food can alter diuretic absorption and put
themselves at even greater risk because they do
not achieve diuretic threshold.  Under fasting
conditions the diuretic is appropriately absorbed,
but a meal may be a significant barrier that
prevents patients from obtaining diuretic
threshold, since every study in this review
showed that food significantly decreased Cmax.
Many patients who are prescribed diuretics also
have compromised renal function as a conse-
quence of their disease, aging, or a combination
of the two.  Aging itself is associated with
decreased renal function and has been the
primary factor associated with age-related
pharmacokinetic differences with the loop
diuretics, furosemide,15 bumetanide,24 and
torsemide.25 With renal insufficiency and aging,
the decreased access of drug to the site of action
warrants larger doses of diuretics to elicit a
response.26 Again, as in patients with heart
failure, any decrease in the amount of diuretic
absorbed may result in not reaching diuretic
threshold and consequent fluid retention.  The
amount of diuretic absorbed is critical for
patients with renal insufficiency, and adminis-
tration of diuretics with food may hinder their
therapy.
These findings may have clinical implications
for patients with heart failure and renal failure
since they are highly dependent on loop diuretics
for fluid control, and any factor that leads to fluid
retention commonly leads to hospitalizations.
Administration of food and loop diuretics
together may significantly reduce the rate of
absorption and the amount of drug that reaches
the kidney, potentially decreasing diuretic
efficacy.  As opposed to patients who have eaten,
those who are fasting are more likely to
experience optimal diuretic pharmacokinetics
(shorter Tmax and greater Cmax) and pharmaco-
dynamics.  Thus, administering loop diuretics
without food maximizes the chances of achieving
a diuretic response to a given dose.
Conclusion
The administration of food and loop diuretics
together may significantly alter the rate of
absorption and the amount of drug that reaches
the kidney.  Clinically, this suggests that the most
effective mode of administering loop diuretics is
without food.  Fasting can be important in
optimizing the ability to reach diuretic threshold
and expediting a response, allowing the clinician
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Figure 2. As seen in these dose-response curves, patients
with chronic heart failure (CHF) have a lower Cmax and
longer Tmax than healthy subjects,12–17 which translates into
a decreased ability to transport drug into the urine when
compared with healthy subjects.
Healthy subjects
Patients
with CHF
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to make timely decisions regarding the patient’s
need for hospitalization and intravenous
diuretics.  Overall, the data suggest that
administering loop diuretics without food will
give clinicians the best chance of having patients
achieve a diuretic response to a given dose.
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